Jon Mcclelland Lockard

Array ( [id] => 15435417 [patent_doc_number] => 20200031892 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => COMPOSITION COMPRISING NEUREGULIN FOR ORGAN PERFUSION, PRESERVATION OR REPERFUSION, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/586589 [patent_app_country] => US [patent_app_date] => 2019-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9730 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16586589 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15363615 [patent_doc_number] => 20200017572 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-16 [patent_title] => VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION [patent_app_type] => utility [patent_app_number] => 16/582486 [patent_app_country] => US [patent_app_date] => 2019-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4799 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16582486 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16222762 [patent_doc_number] => 20200247878 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-06 [patent_title] => Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same [patent_app_type] => utility [patent_app_number] => 16/573966 [patent_app_country] => US [patent_app_date] => 2019-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36410 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16573966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16320174 [patent_doc_number] => 10780121 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-22 [patent_title] => FLT3L-based chimeric proteins [patent_app_type] => utility [patent_app_number] => 16/570553 [patent_app_country] => US [patent_app_date] => 2019-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 37 [patent_no_of_words] => 29114 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16570553 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15589769 [patent_doc_number] => 20200071419 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => ANTIBODIES TO NON-FUNCTIONAL P2X7 RECEPTOR [patent_app_type] => utility [patent_app_number] => 16/568072 [patent_app_country] => US [patent_app_date] => 2019-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9650 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16568072 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15342673 [patent_doc_number] => 20200009228 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-09 [patent_title] => THERAPEUTIC DOSING OF A NEUREGULIN OR A SUBSEQUENCE THEREOF FOR TREATMENT OR PROPHYLAXIS OF HEART FAILURE [patent_app_type] => utility [patent_app_number] => 16/564739 [patent_app_country] => US [patent_app_date] => 2019-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14732 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16564739 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20116046 [patent_doc_number] => 12365735 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-22 [patent_title] => Anti-KLRG1 antibodies [patent_app_type] => utility [patent_app_number] => 17/285793 [patent_app_country] => US [patent_app_date] => 2019-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 7900 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17285793 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17315963 [patent_doc_number] => 20210405011 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => PHARMACEUTICAL FOR PREVENTING AND/OR TREATING STRESS LOAD-RELATED DISEASE [patent_app_type] => utility [patent_app_number] => 17/271300 [patent_app_country] => US [patent_app_date] => 2019-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6303 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17271300 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16748831 [patent_doc_number] => 20210100840 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-08 [patent_title] => SINGLE-CHAIN AND MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/557822 [patent_app_country] => US [patent_app_date] => 2019-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 250541 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16557822 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15239705 [patent_doc_number] => 20190374638 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-12 [patent_title] => SYSTEMS, DEVICES AND METHODS FOR APPLYING ANTI-VEGF COMPOUNDS AND USING SUCH COMPOUNDS TO TREAT SKIN CONDITIONS [patent_app_type] => utility [patent_app_number] => 16/549426 [patent_app_country] => US [patent_app_date] => 2019-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8845 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16549426 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15553491 [patent_doc_number] => 20200061157 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => NON-LEAKING OR MINIMALLY-LEAKING CHOROIDAL OR RETINAL REVASCULARIZATION [patent_app_type] => utility [patent_app_number] => 16/546272 [patent_app_country] => US [patent_app_date] => 2019-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20708 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16546272 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15254147 [patent_doc_number] => 20190375807 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-12 [patent_title] => MODIFIED LIGAND-GATED ION CHANNELS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/544738 [patent_app_country] => US [patent_app_date] => 2019-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18590 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16544738 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15206339 [patent_doc_number] => 20190365856 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => Method of selecting agents for the treatment of pain using neuronal differentiation [patent_app_type] => utility [patent_app_number] => 16/543462 [patent_app_country] => US [patent_app_date] => 2019-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21141 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16543462 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19331322 [patent_doc_number] => 20240245752 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => METHODS FOR EFFECTIVE AND SAFE TREATMENT OF NEUTROPENIA USING DE-MOBILIZED G-CSF [patent_app_type] => utility [patent_app_number] => 16/538853 [patent_app_country] => US [patent_app_date] => 2019-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20083 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16538853 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15206415 [patent_doc_number] => 20190365894 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => HUMAN ENDOTHELIN RECEPTOR ANTIBODY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/538509 [patent_app_country] => US [patent_app_date] => 2019-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20525 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 184 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16538509 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17200110 [patent_doc_number] => 20210340205 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => GFRAL EXTRACELLULAR DOMAINS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/266828 [patent_app_country] => US [patent_app_date] => 2019-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42143 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17266828 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18537542 [patent_doc_number] => 20230242640 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => ANTI-SIRPg Compounds [patent_app_type] => utility [patent_app_number] => 17/270028 [patent_app_country] => US [patent_app_date] => 2019-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16986 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17270028 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15117191 [patent_doc_number] => 20190345228 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-14 [patent_title] => TARGETED THERAPEUTIC AGENTS COMPRISING MULTIVALENT PROTEIN-BIOPOLYMER FUSIONS [patent_app_type] => utility [patent_app_number] => 16/525374 [patent_app_country] => US [patent_app_date] => 2019-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15135 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16525374 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16598113 [patent_doc_number] => 20210024644 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => N-CADHERIN BINDING MOLECULES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/522363 [patent_app_country] => US [patent_app_date] => 2019-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11019 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16522363 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15342713 [patent_doc_number] => 20200009248 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-09 [patent_title] => TARGETING TGR5 TO TREAT DISEASE [patent_app_type] => utility [patent_app_number] => 16/521055 [patent_app_country] => US [patent_app_date] => 2019-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7292 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16521055 [rel_patent_id] =>[rel_patent_doc_number] =>)